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Avoparcin, a glycopeptide antimicrobial agent related
to vancomycin, has been used extensively as a growth pro-
moter in animal feeds for more than 2 decades, and evi-
dence has shown that such use contributed to the
development of vancomycin-resistant enterococci. Acluster
that includes three genes, vanH,  vanA, and vanX, is
required for high-level resistance to glycopeptides. In the
vancomycin producer Amycolatopsis orientalis C329.2,
homologs of these genes are present, suggesting an origin
for the cluster. We found substantial bacterial DNA contam-
ination in animal feed–grade avoparcin. Furthermore,
nucleotide sequences related to the cluster vanHAX are
present in this DNA, suggesting that the prolonged use of
avoparcin in agriculture led to the uptake of glycopeptide
resistance genes by animal commensal bacteria, which
were subsequently transferred to humans. 
A
ntimicrobial resistance in bacterial pathogens is a
major impediment to successful therapy, and in sever-
al instances, bacterial strains have arisen that are refracto-
ry to most available antimicrobial treatments (1).
Resistance arises by mutation (influencing the target or
efflux of the antimicrobial agent) or by the acquisition of
resistance genes (encoding antimicrobial or target alter-
ation, or alternate pathways) (2,3). The actual origins of
acquired resistance genes are unknown, but environmental
microbes, including the strains producing antimicrobial
agents, are believed to be important sources (4,5).
Substantial genetic and biochemical similarities exist
between resistance determinants in antimicrobial
agent–producing actinomycetes and resistance genes
found in gram-positive and gram-negative pathogens
(6–9). 
Since vancomycin-resistant enterococci (VRE) were
clinically isolated in Europe (1986) and the United States
(1987), VRE infections have been reported throughout the
world. These infections may be life-threatening because
choices for alternative treatment are limited. Concomitant
with human use of vancomycin, avoparcin, a closely relat-
ed glycopeptide antimicrobial agent, has been widely used
in Europe and other continents as an animal growth pro-
moter (Figure 1). VRE have been isolated, commonly from
pigs and chickens fed avoparcin-containing animal feed,
and humans coming into contact with the animals (farm
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†University of California, Berkeley, California, USA Figure 1. Chemical structures of avoparcin and vancomycin.workers, butchers) have been shown to carry VRE
(10–12); identical clones have been found (13). The public
health concern about the emergence and dissemination of
VRE in food animals and the food supply caused the
European Union to ban the use of avoparcin in animal feed
in 1997. The discontinued use of avoparcin in animal feed
has resulted in a reduction in the number of vancomycin-
resistant organisms isolated from animals (14,15).
High-level glycopeptide resistance is conferred by a
cluster of three genes, vanH, vanA, vanX (the van cluster),
plus associated regulatory elements; the cluster is often car-
ried by conjugative transposons (16-18). The vanH gene
encodes a D-lactate dehydrogenase that provides the requi-
site D-lactate. vanX encodes a highly specific DD-peptidase
that cleaves only D-Ala-D-Ala produced endogenously
while leaving D-Ala-D-Lac intact. The third gene, vanA,
encodes an ATP-dependent D-Ala-D-Lac ligase.
Replacement of D-Ala-D-Ala by D-Ala-D-Lac in the bacter-
ial cell wall results in a thousandfold reduction in the bind-
ing of glycopeptide antimicrobial agents to their
peptidoglycan target (19). Studies have demonstrated the
presence of vanHAX homologs, such as vanH-ddlN-vanX
(Figure 2), in actinomycete strains producing glycopep-
tides, and strong structural and functional similarity exists
between the various homologs and the van cluster of VRE
(8,9). Some researchers have proposed that the vanH, vanA,
and  vanX genes of hospital enterococci may have been
acquired en bloc from the actinomycetes (8). Related
vanHAX gene clusters have been identified in Paenibacillus
spp. by Patel and coworkers, indicating another possible
source of the van cluster (20). Regardless of the microbial
source, the feeding of crude antimicrobial preparations to
animals is plausible as a delivery process for transferring
the cognate antimicrobial resistance genes between produc-
ing strains and the commensal bacteria of animals (21); the
concomitant selection for resistance would ensure the sur-
vival of rare resistant strains. We provide evidence that a
DNA-encoding homolog of the van cluster is a contaminant
of feed-grade avoparcin and propose that animal use both
created and selected for glycopeptide-resistant strains. The
emergence of vancomycin-resistant Staphylococcus aureus
(VRSA) is a recent sequela to this train of events involving
the van gene clusters (22).
Materials and Methods
DNA Extraction from Avoparcin
A suspension (0.7 mL) of avoparcin (Roche, Sydney,
Australia) in H2O (100 mg/mL) was centrifuged in a 1.5-
mL Eppendorf tube for 6 min and the supernatant, after
being shaken with 1 volume of phenol:chloroform:isoamyl
alcohol (25:24:1), was centrifuged at 16,000 x g for 3 min.
The aqueous phase was subjected to two additional phe-
nol-chloroform extractions. The nucleic acid in the pooled
aqueous fractions was precipitated with ethanol; the pellet
was recovered by centrifugation and further purified by
using a GeneClean spin kit (BIO 101 Systems, Carlsbad,
CA) and resuspended in 100 µL of double-distilled H2O.
The DNA concentration was measured with a fluorometer
(Model TKO100, Hoefer Scientific Instruments, San
Francisco, CA).
PCR Amplification of 16S rDNA Sequences
Primers 16S 440F and 16S 1491R (Table) were
designed to amplify partial 16S rDNAsequences. The poly-
merase chain reaction ([PCR] contained 2 mmol/L MgCl2,
0.16 mmol/L dNTP, 0.4 µmol/L of each primer, Taq poly-
merase (1 U), 3-15 ng template, and 5% dimethyl sulfoxide
(DMSO). PCR was done in a MiniCycler (MJ Research,
Waltham, MA) by using the following program: 96°C, 3
min; 96°C, 30 s; 60°C, 45 s; 72°C, 1 min 30 s; 35 cycles;
and 72°C, 10 min. 
PCR Amplification of vanH, ddlN, 
and vanX Sequences
Different combinations of PCR primers (9) were used
to amplify the entire van cluster (Table). Reaction condi-
tions were as described previously. 
Cloning of vanH, ddlN, vanX, and 
Partial 16S rDNA Genes
PCR products were cloned by using vector pCR 2.1-
TOPO (Invitrogen, Burling, Ontario, Canada) according to
the manufacturer’s instructions, and the insertion size was
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Figure 2. The vanHAX cluster of Amycolatopsis coloradensis
NRRL 3218.
Table. Primer sequences for genes vanH, ddlN, vanX and partial 
16S rDNA 
Primer  Primer sequences 
vanH-1  5′-CAC ATC GA(C/T) GTG GAA TAC GC-3′ 
vanH-2  5′-CAG TCG GCG TAG AAG ATG CC-3′ 
vanH-3  5′-GAG GAA GGC ATC TTC TAC GC-3′ 
ddlN-1  5′-ACG (G/C)CA GTA CGA C(G/T)C GAA G-3′ 
ddlN-2  5′-T(G/T)C CTG GA(A/T) GCT (G/C)TG CGA C-3′ 
ddlN-3  5′-G(A/G)T AAC GGC TGT ACG AGG TC-3′ 
vanX-3  5′-CCA CGT GGG ACA ACT TCA C-3′ 
vanX-4  5′-CAG (C/G)(G/T)T GTA GTG CCA CCA CTC-3′ 
vanX-5  5′-TCA CCA GAT ATC CGT CCA CC-3′ 
16S 440F  5′-AGC AGG GAA GAA GCG (A/T/C)(A/G)A GT-3′ 
16S 1491R  5′-CGG CTA CCT TGT TAC GAC TTC-3′ confirmed by a second PCR. Plasmid DNA was extracted
by using the Concert rapid plasmid miniprep system
(Invitrogen).
DNA Sequence Analysis
Cycle sequence reactions were carried out with a
BigDye terminator DNA sequencing kit (Applied
Biosystems, Foster City, CA) with plasmid DNA tem-
plates. The cycle sequence program was as follows: 96°C,
1 min; 96°C, 30 s; 50–60°C (dependent on different
primers and fragments), 15 s; 60°C, 4 min, for 25 cycles.
Excess oligos and dyes were removed by using CentriSep
spin columns (Princeton Separations, Aldelphia, NJ).
Reaction products were sequenced by the Nucleic Acid
and Protein Service, University of British Columbia, using
an ABI PRISM 377 sequencer. Sequences were analyzed
by using the standard nucleotide-nucleotide BLAST pro-
gram (National Center for Biotechnology Information,
Bethesda, MD). and comparisons were carried out by
using CLUSTAL W (European Bioinformatics Institute,
Cambridge, UK).
Results and Discussion
Direct extraction of avoparcin powder with
phenol/chloroform/isoamyl alcohol provided substantial
amounts of DNA (30.5 µg/g of avoparcin) (Figure 3A).
PCR amplification of the DNA with oligonucleotide
primers specific for a region of streptomycete 16S rRNA
gave a single amplicon (Figure 3B), which was sequenced
and shown to be 16S closely related to that of
Amycolatopsis coloradensis, the producer of avoparcin.
Figure 3B shows similarities between the 16S rRNA of
species that produce glycopeptide antimicrobial agents.
To examine for the presence of genes involved in gly-
copeptide resistance from the antimicrobial agent–derived
DNA, we used the DNAprimers described by Marshall et
al. (9). The amplicons (Figure 4) were cloned, sequenced,
and assembled, indicating a van-like cluster closely relat-
ed to that found in A. orientalis and Streptomyces toy-
ocaensis. Control reactions run without added template
were negative.
The genes encoded three putative proteins showing
>50% amino acid identity to the Van H, A, and X proteins
of VRE (Figure 2). All of the clusters have translational
overlaps between the vanA and  vanX genes and their
homologs, suggesting cotranslational regulation of
expression. This finding clearly implies that the van clus-
ter must be transferred and acquired in toto from any
source organism. 
We suggest that the use of crude avoparcin preparations
in animal feeds from 1975 to 1996 was the origin of the
vanHAX cluster in the genesis of VRE (and possibly that
found in VRSA) (22,23). Large amounts of avoparcin were
used in animal feed; in Denmark, for example, total van-
comycin use in 1994 amounted to 24 kg, whereas avoparcin
use in animals was 24,000 kg (24). During their entire lives,
broiler chickens received 15 mg/kg and pigs 20–40 mg/kg
of antimicrobial agent in their feed. Each pig was fed 5–10
g of the crude drug for its life span and, consequently,
received a steady dose of DNA encoding vancomycin
resistance. In Europe, an estimated 100 mg of antimicrobial
agents are used in animal feed for the production of 1 kg of
meat for human consumption. We believe that this regimen
would have favored the selection and maintenance of rare
bacterial transformants carrying the resistance genes. If one
bears in mind that large numbers of pigs and chickens were
exposed to the antimicrobial agent, the probability of gene
pick-up by bacterial commensals in the animal gastroin-
testinal tract would be favored, and once incorporated into
a gut commensal genome, further dissemination would
have followed under antimicrobial selection. The finding
that organization of the van cluster in contaminating DNA
of the feed is identical to that in VRE, with overlapping
reading frames typical of translational coupling of gene
expression between the vanA and vanX homologs (9), rein-
forces this supposition. 
The mechanism by which a van cluster becomes func-
tionally integrated into bacteria is not known. We propose
that intestinal bacteria were the original recipients of the
DNA; many of the resident strains are known to be com-
petent for DNA uptake (25,26). However, mere uptake is
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Figure 3. A, Molecular mass of total DNA extracted from animal
feed–grade avoparcin. M: 1 kb plus DNA ladder (Invitrogen,
Burlington, Ontario, Canada). Lane 1: sample of total DNA extract-
ed from animal feed–grade avoparcin. B, Polymerase chain reac-
tion amplification of partial 16S rDNA (1051 bp) with primers 16S
440F and 16S 1491R. M:1 kb plus DNA ladder. Lane 1: DNA
extracted from animal feed–grade avoparcin. Lane 2: DNA of the
avoparcin producer Amycolatopsis coloradensis NRRL 3218.
A Bnot sufficient for function, and the actinomycete genes dif-
fer from VRE genes in their G+C content (approximately
65% vs. 50%) and codon usage. Given the enormous com-
plexity of bacterial populations in the mammalian gas-
trointestinal tract (27,28), we assume that a variety of
intestinal species may have incorporated the resistance-
encoding DNA; expression (at low levels) would have
been rare, depending on the compatibility of the van genes
with the transcription and translation system of the host.
Under constant antimicrobial selection pressure, transla-
tionally competent sequences would have developed by
mutation; this would not necessarily have occurred in ente-
rococci. Nonetheless, the conversion (evolution) of the
actinomycete genes into functional enterococcal genes
likely would have required many generations of growth
under constant selection, and any intermediate stages in
this process are a matter of speculation; however, once
established on conjugative transposons, the genes would
be readily disseminated (17,29). A number of similar van
clusters have been identified in different bacterial species,
and whether these evolved independently or by divergent
evolution is unknown. 
The finding of resistance genes in crude antimicrobial
products intended to be fed to animals adds to the already
strongly voiced opinion that use of antimicrobial agents in
this way constitutes a serious public health concern and
further emphasizes the need for prohibiting the use in ani-
mal feed of all antimicrobial agents that are employed in
human therapy. This ban should include structurally or bio-
logically related antimicrobial agents and the use of any
compound with the potential to select for cross-resistance
to another antimicrobial agent (15,30). The use of
avoparcin in Denmark was prohibited in 1995 and in the
European Union in 1997. Subsequently, several other
antimicrobial growth promoters were banned (31,32).
However, the United States and Canada permit the use of
many such products, including penicillin, tetracycline,
macrolides, and sulfonamides. Nonhuman applications of
antimicrobial agents, such as in agriculture and aquacul-
ture, should employ only chemically and biologically dis-
tinct classes of compounds developed specifically for that
purpose. Clearly such measures should be combined with
a requirement for rational and prudent measures for
antimicrobial use in the human population. 
Many antimicrobial agents (or their close structural rel-
atives) have been used extensively as animal-feed addi-
tives. In almost all cases, crude antimicrobial preparations
are used, and thus the antimicrobial agent acts as a carrier
for its cognate resistance genes. These delivery systems
provide the opportunity for resistant strains of bacteria to
evolve and so create an enormous gene pool for antimicro-
bial resistance determinants in the environment.
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